Madrigal Pharmaceuticals
MDGL
151 hedge funds and large institutions have $1.09B invested in Madrigal Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 37 reducing their positions, and 17 closing their positions.
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
62% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 37
15% more call options, than puts
Call options by funds: $5.62M | Put options by funds: $4.91M
10% more funds holding
Funds holding: 137 → 151 (+14)
8.47% less ownership
Funds ownership: 76.17% → 67.71% (-8.5%)
23% less capital invested
Capital invested by funds: $1.43B → $1.09B (-$334M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$28.6M |
| 2 |
Citigroup
New York
|
+$19.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$11.6M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$11.3M |
| 5 |
LC
L1 Capital
Melbourne VIC 3000,
Australia
|
+$6.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$169M |
| 2 |
Morgan Stanley
New York
|
-$20M |
| 3 |
Two Sigma Investments
New York
|
-$13.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.3M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.65M |
MDGL Hedge Fund Activity: Q2 2021 in Review
151 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2021, worth a combined $1.09B — down 23% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MDGL positions and 17 closed out — a net gain of 14 holders — while 60 added to existing stakes and 37 trimmed.
The largest buyer was Armistice Capital, adding an estimated $28.6M. The largest seller was Capital Research Global Investors, cutting an estimated $169M.
- 151 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2021, up from 137 in Q1 2021.
- Funds reported $1.09B of Madrigal Pharmaceuticals stock for Q2 2021, down 23% quarter-over-quarter.
- 31 funds opened new Madrigal Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +14 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2021 was Armistice Capital, an estimated $28.6M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2021 was Capital Research Global Investors, an estimated $169M sold.
Based on aggregated 13F filings for Q2 2021.